Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - apramycin - oral powder, pre-mix - apramycin antibiotic active 50.0 g - antibiotic & related - calf | pigs | poultry broilers (meat for human consum) | beef calf | boar | bovine | calf - poddy | calf - preweaning | calf - s - antibiotics - oral, parenteral | colibacillosis | enteritis associated with e.coli | salmonella spp. | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tilmicosin phosphate - oral powder, pre-mix - tilmicosin phosphate antibiotic active 200.0 g/kg - antibiotic & related - pigs | boar | gilt | piglet | sow | swine - pneumonia | bacterial pneumonia

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - monensin sodium - oral powder, pre-mix - monensin sodium antiprotozoal active 100.0 g/kg - nutrition & metabolism - cattle | cattle - feedlot | dairy cattle | goat | pasture cattle | poultry broilers (meat for human consum) | pullet-laying repl - bloat | coccidiosis | improve feed efficiency | improve reproductive performance | improvement of milk production | ketosis | productivity improvements | acetonaemia | bloated | colic | eimeria acervulina | eimeria brunetti | eimeria maxima | eimeria mivati | eimeria necatrix | eimeria tenella | elevated ketones | frothy bloat | gas colic | improving feed efficiency | increasing rate of weight gain | legume bloat | non-clinical ketosis | weight gain

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - monensin as monensin sodium - misc. intra ruminal device - monensin as monensin sodium antiprotozoal active 32.0 g/cp - alimentary system

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - ivermectin - topical solution/suspension - ivermectin anthelmintic active 16.0 g/l - parasiticides

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - temephos; liquid hydrocarbon - topical solution/suspension - temephos organophosphorus-dithiophospha active 350.0 g/l; liquid hydrocarbon solvent other 492.0 g/l - parasiticides

Bandaríkin - enska - NLM (National Library of Medicine)

shionogi inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen 375 mg - carefully consider the potential benefits and risks of naprelan®  tablets and other treatment options before deciding to use naprelan®  tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). naprelan®  tablets are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout. it is also indicated in the relief of mild to moderate pain and the treatment of primary dysmenorrhea. naprelan®  is contraindicated in patients with known hypersensitivity to naproxen. naprelan®  should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings- anaphylactoid reactions, and precautions- preexisting asthma). naprelan®  is contraindicated for the treatment of peri-operative pain in the setting of corona

Bandaríkin - enska - NLM (National Library of Medicine)

almatica pharma inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen 375 mg - naprelan tablets are indicated for the treatment of: • rheumatoid arthritis (ra) • osteoarthritis (oa) • ankylosing spondylitis (as) • tendinitis, bursitis • acute gout • primary dysmenorrhea (pd) • the relief of mild to moderate pain [see warnings and precautions (5)] . naprelan is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] risk summary use of nsaids, including naprelan, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios an

Írland - enska - HPRA (Health Products Regulatory Authority)

elanco gmbh - flubendazole - oral powder - 50 milligram(s)/gram - flubendazole

Ísrael - enska - Ministry of Health

medison pharma ltd - setmelanotide - solution for injection - setmelanotide 10 mg / 1 ml - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet-biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.